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Abstract
In the current issue of Critical Care, Friesenecker and colleagues
present a well-designed comparative study on the microvascular
effects of arginine vasopressin (AVP) and norepinephrine (NE) in a
physiological, unanesthetized hamster model. The authors clearly
demonstrate that AVP, but not NE, has marked vasoconstrictive
effects on large arterioles, whereas the impact on small arterioles is
comparable for both vasopressors. However, it remains unclear if
these results, per se, reflect a stronger vasopressive potential of
AVP versus NE, as macrohemodynamic variables were not
different between study groups. Since the authors did not
investigate the effects of AVP and NE in vasodilatory shock states,
the microcirculatory response in sepsis or systemic inflammatory
response syndrome remains inconclusive. The same authors
previously reported that AVP infusion in patients suffering from
vasodilatory shock carries the risk for ischemic skin lesions. This in
turn raises the question whether the quality of vasopressors should
be judged by their potency.
In the current issue of Critical Care, Friesenecker and
colleagues [1] present a well-designed comparative study on
the microvascular effects of arginine vasopressin (AVP) and
norepinephrine (NE) in awake hamsters under physiological
conditions. The authors used the dorsal skinfold window
chamber technique to measure vascular diameter, cross-
sectional area and blood flow of five different sizes (A0 to A4)
of subcutaneous arterioles. Whereas continuous infusion of
both drugs resulted in similar macrohemodynamic changes,
AVP led to a more pronounced reduction in vessel diameter
and blood flow of the proximal, large (A0) arterioles than NE.
Interestingly, both vasopressors had similar effects on the
skin microvasculature in more distal, smaller (A1 to A4)
arterioles. From these results the authors conclude that the
strong vasoconstrictive effect of AVP on large arterioles
accounts for its strong vasopressive potency and may explain
its efficacy in catecholamine-refractory vasodilatory shock.
To the best of our knowledge, Friesenecker and colleagues
are the first to have compared the effects of AVP and NE on
different subcutaneous vessel calibers. Nevertheless, the
study has to face some criticism.
First of all, the conclusion that especially the vasoconstrictive
effect of AVP on large (A0) arterioles accounts for its strong
vasopressor effect cannot be drawn from the presented data.
In this context it is especially noteworthy that the authors
observed differences in neither macrohemodynamics (i.e.
mean arterial pressure (MAP)) nor microcirculatory effects on
A1 to A4 arterioles between both study groups. The fact that
the stronger vasoconstrictive effect of AVP on A0 arterioles
was the only difference between groups suggests that the
constriction of large arterioles had (almost) no impact on total
peripheral resistance. This thesis is supported by Poiseuille’s
law implying that resistance is inversely correlated to the
fourth power of the vessel radius. Accordingly, the small
vessels primarily account for changes in vascular resistance
rather than the large ones [2].
Using the same animal model, Gerstberger and colleagues
[3] compared the effects of either 10 pmoles/kg of AVP or
the same dose of angiotensin (ANG) II on the hamster
subcutaneous microcirculation. These authors reported that
the vasoconstrictive effects of both drugs on small (A3)
arterioles were comparable, whereas ANG II, but not AVP,
contributed to a marked constriction of greater (A1)
arterioles. This vasoconstriction of A1 arterioles by ANG II
was associated with a much greater vasopressor effect (i.e.
change in MAP) than AVP. Notably, the AVP plasma levels
measured in the study by Gerstberger and colleagues were
about 100 pg/ml, thus representing the upper therapeutic
range during AVP infusion in patients with hyperdynamic
septic shock [4]. The contradictory results of Friesenecker
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and colleagues [1] and Gerstberger and colleagues [3]
emphasize that the effects of vasoactive agents on the
microcirculation are still not fully understood. Therefore, the
study of Friesenecker and colleagues [1] gives another
important and interesting insight into the diversity of the
microvascular response to vasoconstrictor agents.
With respect to the second conclusion, the study by
Friesenecker and colleagues would have certainly profited
from studying groups suffering from vasodilatory shock
secondary to systemic inflammation. This holds especially
true, since clinical and experimental research has clearly
shown that distribution abnormalities in vasodilatory shock
states contribute to significant changes in microvascular
hemodynamics [5]. Therefore, interventions in the physio-
logical state may not necessarily be suitable to predict the
response of the same intervention under pathological
conditions, such as sepsis.
Finally, although redistribution of blood flow away from non-
vital organs (e.g. the skin) to vital organs represents one of
the primary therapeutic aims of vasopressor therapy
(especially in septic shock patients), it should be kept in mind
that this approach may result in severe hypoperfusion of non-
vital organs. Whereas it is well known that AVP infusion
(especially when applied in higher doses) increases the risk
of gut mucosal ischemia [6], skin hypoperfusion appears to
be another clinically relevant complication. In this regard, the
study group of Friesenecker and Dunser recently reported on
the incidence and risk factors of ischemic skin lesions in
patients with catecholamine-resistant vasodilatory shock [7].
Importantly, the authors found that ischemic skin lesions are
common among patients with vasodilatory shock treated with
AVP and that the combination of sepsis and treatment with
AVP may especially be a risk factor for the development of
ischemic skin lesions.
In conclusion, Friesenecker and colleagues [1] correctly state
that AVP has a stronger vasoconstrictive effect on large
arterioles of the subcutaneous vasculature in healthy hamsters
compared to NE. Unfortunately, the very interesting question
of whether or not the stronger vasoconstrictive effect on large
vessels is also maintained in vasodilatory shock remains
unresolved. The fact that AVP infusion may impair gut mucosal
microcirculation [6] and skin perfusion [7] suggests that the
stronger one may not necessarily be the better one.
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